RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. Co. is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. We show 23 historical shares outstanding datapoints in our coverage of RAPT's shares outstanding history.
Understanding the changing numbers of RAPT shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like RAPT versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching RAPT by allowing them to research RAPT shares outstanding history
as well as any other stock in our coverage universe. |
Free RAPT Email Alerts:
Video: Shares Outstanding Importance
